Phase 3 N=19 Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
Immune Thrombocytopenia
Primary: Cumulative Number of Weeks of Platelet Response — 13.47 cumulative number of weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18,578 CV Wizard: Does a Clinical Decision Support Tool Improve CVD Risk Factor Control in Safety Net Clinics?
Heart Attack · Stroke · Cardiovascular Diseases
Primary: 1-year Change in 10-year CVD Risk — 0.4; 0.2 percent risk of CVD
N/A N=50 Theranostic Guided Riboflavin/UV-A Corneal Cross-linking
Keratoconus
Primary: Validation of the Theranostic Scores — 91; 95 Percentage
Phase 3 N=14,727 A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Respiratory Tract Infection
Primary: Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)…
N/A N=19 Balance Training With tDCS for CAI
Ankle Injuries and Disorders
Primary: Static Postural Balance — 57.0; 55.9 CM/S
Phase 1 N=16 A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Etrasimod — 1620; 1529; 1538; 1391…
Phase 2 N=22 Single Dose IV Methadone for Post-Op Pain
Pain, Postoperative
Primary: Pharmacokinetics (PK) in Adults - Systemic Clearance (CL) — 6.14 liters/hour
Phase 3 N=160 Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy
Cystectomy
Primary: VAS Score at 48 Hour — 5; 7; 4; 6 score on a scale
Phase 2 N=66 A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Hodgkin's Lymphoma · Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Primary: Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator — 66.7; 50.0 Percentage of Participants
Phase 2 N=62 Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
Carcinoma, Non-Small-Cell Lung
Primary: Toxicity Rate — 18; 42 Participants
Phase 4 N=132 Monitoring Anti-Dementia Drugs by Serum Levels
Dementia · Dementia With Lewy Bodies · Dementia in Parkinsons Disease
Primary: Change of Mini Mental State Examination (MMSE) Test Result — -0.27; -0.90 difference in MMSE units on a scale
Phase 3 N=123 SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
Non-infectious Anterior Uveitis
Primary: Number of Subjects Who Meet Time to Clearance of Anterior Chamber Cells — 25; 24 Subjects
N/A N=20 Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Adult Rhabdomyosarcoma · Lung Metastases · Metastatic Ewing Sarcoma
Primary: Feasibility of Delivering Cardiac-sparing IMRT With Central Quality Control in 20 Subjects — 20 Participants
N/A N=36 A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Acute Myeloid Leukemia · Myelodysplastic Syndromes
Primary: Feasibility - Retention Rate — 19; 6; 10 Participants
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units